| 1. |
|
|
| 2. |
- Bartoletti, Stefania, et al.
(författare)
-
Positioning methods
- 2024
-
Ingår i: Positioning and Location-based Analytics in 5G and Beyond. - 9781119911463 ; , s. 21-50
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- This chapter introduces the main positioning methods, starting from the state-of-the-art and following a statistical estimation perspective. This is followed by an in-depth treatment of radio positioning, first focusing on device-based positioning and then on device-free positioning. Finally, recent approaches based on artificial intelligence methods for positioning are detailed.
|
|
| 3. |
- Broberg, K., et al.
(författare)
-
OS03-11 Exposure to PFAS and associated toxicity in workers exposed to hexavalent chromium – a cross-sectional study within the SafeChrom project : Abstracts of the 58th Congress of the European Societies of Toxicology (EUROTOX 2024)
- 2024
-
Ingår i: Toxicology Letters. - 0378-4274. ; 399:Supplement 2, s. 67-67
-
Konferensbidrag (övrigt vetenskapligt/konstnärligt)abstract
- BackgroundThis study aimed to investigate the exposure to perfluoroalkyl substances (PFAS) and cancer-related toxicity in workers in different Swedish industry sectors with exposures to hexavalent chromium (Cr(VI)).MethodsThe study consisted of 111 exposed workers and 72 controls. The exposed workers were performing manufacture/processing of metal products (n=55), working in steel production (n=31), bath plating (n=17), a nd o thers (n=8). T he P FAS e xposure w as a ssessed b y t he determination of ten PFAS in serum samples by LC-MS/MS. Cr was measured in red blood cells (RBC) by ICP-MS, as a long-term marker for Cr(VI) exposure. Telomere length and DNA methylation of lung cancer-related genes in DNA from peripheral blood were measured by qPCR and pyrosequencing, respectively.ResultsSignificant differences between workers with Cr(VI) exposure and controls were found for the PFHpA and PFOA (P<0.001, linear regression analysis adjusted for age). There were significant differences between occupational groups where the bath platers showed significantly higher levels of PFHpA, PFHPS, PFPeS, PFOS, PFDS, and PFHxS compared with the other occupational groups. The highest serum concentration was found for PFOS: 700 ng/ml in a bath plater, to be compared with the median concentration of 3.82 ng/ml among the controls. PFOA and PFHPS correlated positively with RBC-Cr (rS=0.27 and 0.35 respectively) in exposed workers. PFOA was associated with shorter telomere length after adjustment for age. No clear associations was found for DNA methylation in cancer-related genes. Ongoing analysis will assess mixture effects on toxicity biomarkers.ConclusionThe considerably high PFAS exposure in Cr(VI) bath platers can be explained by the former application of PFAS as mist suppressants in electroplating baths but further sources of exposure should be examined. The association between PFAS and some cancer-related biomarkers warrants further examination, including potential mixture effects.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Jendle, Johan, 1963-, et al.
(författare)
-
Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4)
- 2014
-
Ingår i: Diabetologia. - : Springer Science and Business Media LLC. - 0012-186X .- 1432-0428. ; 57:Suppl 1, s. S23-S24
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Background and aims: This 52 week, parallel-arm, open-label, phase 3 study compared two doses of the once weekly GLP-1 receptor agonist dulaglutide (DU) versus bedtime insulin glargine, all combined with pre-meal insulin lispro with or without metformin, in patients with type 2 diabetes mellitus inadequately controlled on conventional insulin therapy. Insulin glargine and insulin lispro were titrated to attempt to reach glycaemic targets.Materials and methods: Patients (N = 884; mean baseline characteristics: age 59.4 years; duration of diabetes 12.7 years; HbA1c 8.5%; body weight 91.1 kg; BMI 32.5 kg/m2; total daily insulin dose 56 U) were randomised (1:1:1) to once weekly DU 1.5 mg, DU 0.75 mg, or bedtime insulin glargine titrated-to-target. The primary objective was to compare the change in HbA1c from baseline of DU 1.5 mg with insulin glargine at 26 weeks for noninferiority (margin 0.4%) and if met, then superiority was tested.Results: At 26 and 52 weeks, both DU doses were statistically superior to insulin glargine for HbA1c change from baseline. Insulin glargine was associ-ated with greater fasting serum glucose reduction compared with both DU doses. The mean prandial insulin doses at 26 weeks were 93 U for DU 1.5 mg, 97 U for DU 0.75 mg, and 68 U for insulin glargine. The insulin glargine dose was 65 U. Similar insulin doses were observed at 52 weeks. Body weight decreased with DU 1.5 mg and increased with DU 0.75 mg and insulin glar-gine at 52 weeks. The rate of documented symptomatic hypoglycaemia (≤3.9 mmol/L) at 52 weeks was 31.0, 35.0,and 39.9 events/patient/year for DU 1.5 mg, DU 0.75 mg, and insulin glargine, respectively. The number of severe hypoglycaemia events was 11 for DU 1.5 mg, 15 for DU 0.75 mg, and 22 for insulin glargine. Nausea, diarrhoea, and vomiting were more common with DU 1.5 mg (25.8%, 16.6%, and 12.2%, respectively) and DU 0.75 mg (17.7%, 15.7%, and 10.6%) versus insulin glargine (3.4%, 6.1%, and 1.7%).Conclusion: DU compared to insulin glargine, both combined with insu-lin lispro, resulted in better glycaemic control, less body weight gain, no in-creased risk of hypoglycaemia, and more common reporting of gastrointes-tinal adverse events.
|
|
